DSGN Quote, Financials, Valuation and Earnings

Kodiak Sciences has a net margin of -- compared to Design Therapeutics's net margin of --. Design Therapeutics's return on equity of -- beat Kodiak Sciences's return on equity of --.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 90.97%. On the other hand Kodiak Sciences has an analysts' consensus of $6.80 which suggests that it could grow by 75.26%. Given that Design Therapeutics has higher upside potential than Kodiak Sciences, analysts believe Design Therapeutics is more attractive than Kodiak Sciences.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kodiak Sciences has a beta of 2.266, suggesting its more volatile than the S&P 500 by 126.64%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Kodiak Sciences pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Kodiak Sciences quarterly revenues of --. Design Therapeutics's net income of -$17.7M is higher than Kodiak Sciences's net income of -$57.5M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Kodiak Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus -- for Kodiak Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -- compared to Design Therapeutics's net margin of -67.73%. Design Therapeutics's return on equity of -- beat Quanterix's return on equity of -14.39%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 90.97%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 85.64%. Given that Design Therapeutics has higher upside potential than Quanterix, analysts believe Design Therapeutics is more attractive than Quanterix.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quanterix has a beta of 1.055, suggesting its more volatile than the S&P 500 by 5.534%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Quanterix quarterly revenues of $30.3M. Design Therapeutics's net income of -$17.7M is higher than Quanterix's net income of -$20.5M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 1.74x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Sunshine Biopharma has a net margin of -- compared to Design Therapeutics's net margin of -13.25%. Design Therapeutics's return on equity of -- beat Sunshine Biopharma's return on equity of -21.04%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 90.97%. On the other hand Sunshine Biopharma has an analysts' consensus of $140.00 which suggests that it could grow by 8932.26%. Given that Sunshine Biopharma has higher upside potential than Design Therapeutics, analysts believe Sunshine Biopharma is more attractive than Design Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sunshine Biopharma has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.364%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sunshine Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Sunshine Biopharma pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Sunshine Biopharma quarterly revenues of $8.9M. Design Therapeutics's net income of -$17.7M is lower than Sunshine Biopharma's net income of -$1.2M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Sunshine Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 0.07x for Sunshine Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -- compared to Design Therapeutics's net margin of -15.34%. Design Therapeutics's return on equity of -- beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 90.97%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.10 which suggests that it could grow by 44.83%. Given that Design Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Design Therapeutics is more attractive than Xeris Biopharma Holdings.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.451%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Xeris Biopharma Holdings quarterly revenues of $60.1M. Design Therapeutics's net income of -$17.7M is lower than Xeris Biopharma Holdings's net income of -$9.2M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 2.93x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.